Press Release: AMN Healthcare Announces THIRD Quarter 2026 Results

Dow Jones11-06

Quarterly revenue of $717 million and adjusted EBITDA of $94 million;

GAAP net income of $0.83/share and adjusted EPS of $1.16

DALLAS, Nov. 5, 2026 /PRNewswire/ -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its third quarter 2026 financial results. Financial highlights are as follows:

Dollars in millions, except per share amounts.

 
                                                                  % Change 
                                 % Change Q3        YTD              YTD 
                        Q3 2026      2025      Sept. 30, 2026   Sept. 30, 2025 
----------------------  -------  -----------  ---------------  --------------- 
Revenue                 $717.3      13 %         $2,768.9           40 % 
----------------------  -------  -----------  ---------------  --------------- 
Gross profit            $229.1      24 %          $803.8            39 % 
----------------------  -------  -----------  ---------------  --------------- 
Net income               $33.4      14 %          $116.7             nm 
----------------------  -------  -----------  ---------------  --------------- 
GAAP diluted EPS         $0.83       9 %           $2.93             nm 
----------------------  -------  -----------  ---------------  --------------- 
Adjusted diluted EPS*    $1.16      199 %          $4.01            252 % 
----------------------  -------  -----------  ---------------  --------------- 
Adjusted EBITDA*         $93.6      63 %          $333.1            85 % 
----------------------  -------  -----------  ---------------  --------------- 
 

(* See "Non-GAAP Measures" below for a discussion of our use of non-GAAP items and the table entitled "Non-GAAP Reconciliation Tables" for a reconciliation of non-GAAP items.)

Business Highlights

   -- Third quarter revenue and earnings exceeded guidance, driven by our 
      travel nurse and allied businesses and a labor disruption reserve 
      release. 
 
   -- Demand for travel nursing and allied strengthened further, and our strong 
      execution drove volume up double digits over prior year and revenue 
      growth for a third straight quarter. 
 
   -- Search revenue grew 15% year over year with strength across executive 
      search and physician permanent placement. 
 
   -- Locum tenens results were on track with our expectations amid the 
      business's ongoing process and technology transformation. 
 
   -- Our quarter-end cash balance was $256 million with a leverage ratio, 
      calculated under the terms of our credit agreement, of 1.3x. 

"We are encouraged by the continued growth in nursing and allied staffing. Demand strengthened during the third quarter and through October and our team is delivering for our clients through faster recruiting, automation, and around-the-clock execution. We also are making progress on improvements in our other segments," said Cary Grace, President and Chief Executive Officer of AMN Healthcare. "Healthcare organizations increasingly want better visibility and more strategic management of their total workforce. Our strategy to bring together our talent engagement, trusted client relationships, operational expertise, and technology-enabled solutions is well-timed with the marketplace's demands."

Third Quarter 2026 Results

Consolidated revenue for the quarter was $717 million, a 13% increase from the prior year and a 7% increase from the prior quarter. Net income was $33 million (4.7% of revenue), or $0.83 per diluted share, compared with net income of $29 million (4.6% of revenue), or $0.76 per diluted share in the third quarter of 2025. Adjusted diluted EPS in the third quarter was $1.16 compared with $0.39 in the same quarter a year ago.

Revenue for the Nurse and Allied Solutions segment was $460 million, higher by 27% year over year and up 9% from the prior quarter, driven by core nurse and allied businesses and labor disruption reserve releases from prior events we supported. Travel nurse staffing revenue was higher by 19% year over year and up 2% sequentially. Allied division revenue increased 11% year over year and was flat sequentially. Labor disruption contributed $59 million revenue in the quarter compared to $25 million in the prior quarter and $12 million in the year-ago quarter.

The Physician and Leadership Solutions segment reported revenue of $171 million, down 4% year over year and up 4% sequentially. Locum tenens revenue was $138 million, down 5% year over year and up 6% sequentially. Interim leadership revenue was down by 5% year over year and flat sequentially. Search revenue increased 15% year over year and was down 9% sequentially.

Technology and Workforce Solutions segment revenue was $86 million, a decrease of 9% year over year and 1% sequentially. Language services revenue was $69 million in the quarter, down 8% from the prior year and 1% sequentially. Vendor management systems revenue was $15 million, 11% lower year over year and flat from the prior quarter.

Consolidated gross margin was 31.9%, 280 basis points higher year over year and up 130 basis points sequentially. Higher margin in the Nurse and Allied Solutions segment, driven by the labor disruption reserve release, drove the sequential improvement.

Consolidated SG&A expenses were $149 million, or 20.8% of revenue, compared with $139 million, or 21.8% of revenue, in the same quarter last year. SG&A was $147 million, or 21.9% of revenue, in the previous quarter. The year-over-year increase in SG&A expenses was primarily due to liability insurance expense and the allowance for credit losses.

Income from operations was $51 million with an operating margin of 7.0%, compared with income of $48 million and 7.5%, respectively, in the same quarter last year. Adjusted EBITDA was $94 million, a year-over-year increase of 63%. Adjusted EBITDA margin was 13.0%, 390 basis points higher than the year-ago period.

At September 30, 2026, cash and cash equivalents totaled $256 million. Cash flow from operations was ($88 million) for the third quarter and $285 million year to date. The sequentially lower cash balance and negative operating cash flow resulted from refunding the majority of client deposits related to previous labor disruption events. Capital expenditures were $10 million in the third quarter, and we used $8.4 million to repurchase 250,685 shares at an average price of $33.50. The Company ended the quarter with total debt outstanding of $750 million with nothing drawn on our revolving credit facility.

Fourth Quarter 2026 Outlook

 
             Metric                      Guidance* 
---------------------------------  ---------------------- 
      Consolidated revenue            $655 - $670 million 
---------------------------------  ---------------------- 
          Gross margin                 25.7% - 26.2% 
---------------------------------  ---------------------- 
   SG&A as percentage of revenue       21.2% - 21.7% 
---------------------------------  ---------------------- 
        Operating margin               (0.1%) - 0.5% 
---------------------------------  ---------------------- 
     Adjusted EBITDA margin             5.8% - 6.3% 
---------------------------------  ---------------------- 
 

(*Note: Guidance percentage metrics are approximate. For a reconciliation of adjusted EBITDA margin, see the table entitled "Reconciliation of Guidance Operating Margin to Guidance Adjusted EBITDA Margin" below.)

Revenue in the fourth quarter of 2026 is expected to be 10-12% lower than the prior year. This outlook assumes labor disruption revenue of $5 million this quarter compared with $124 million in Q4 2025. Nurse and Allied Solutions segment revenue is expected to be down 13-15% year over year, or up 13-15% excluding labor disruption. Physician and Leadership Solutions segment revenue is expected to be down 5-7% year over year. Technology and Workforce Solutions segment revenue is projected to be down 8-10% year over year.

Fourth quarter estimates for certain other financial items include depreciation of $12.5 million, depreciation in cost of revenue of $2.5 million, amortization expense of $15.5 million, share-based compensation expense of $6 million, integration and other expenses of $2 million, interest expense of $8.5 million, marginal adjusted tax rate of 28%, and 40.1 million diluted average shares outstanding.

Conference Call on November 5, 2026

AMN Healthcare Services, Inc. (NYSE: AMN) will host a conference call to discuss its third quarter 2026 financial results and fourth quarter 2026 outlook on Thursday, November 5, 2026 at 5:00 p.m. Eastern Time. A live webcast of the call can be accessed through AMN Healthcare's website at http://ir.amnhealthcare.com. Interested parties may participate live via telephone by registering at this link. Please follow the link and register with a valid e-mail address. After registering, the system will call you instantly and connect you into the conference call automatically.

Alternatively, you may dial in to the conference call by calling 1-646-357-8785 or 1-800-836-8184 and you will be connected to the call by an operator.

About AMN Healthcare

AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the United States. The Company provides access to the most comprehensive network of quality healthcare professionals through its innovative recruitment strategies and breadth of career opportunities. With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency and improve patient outcomes. AMN total talent solutions include managed services programs, clinical and interim healthcare leaders, temporary staffing, direct hire and retained search solutions, vendor management systems, recruitment process outsourcing, predictive modeling, language interpretation services, revenue cycle solutions, credentialing, and other services. Clients include acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, schools, and many other healthcare settings. AMN Healthcare is committed to fostering and maintaining a diverse team that reflects the communities we serve. Our commitment to the inclusion of many different backgrounds, experiences and perspectives enables our innovation and leadership in the healthcare services industry.

The Company's common stock is listed on the New York Stock Exchange under the symbol "AMN." For more information about AMN Healthcare, visit www.amnhealthcare.com, where the Company posts news releases, investor presentations, webcasts, SEC filings and other material information. The Company also utilizes email alerts and Really Simple Syndication ("RSS") as routine channels to supplement distribution of this information. To register for email alerts and RSS, visit http://ir.amnhealthcare.com.

Non-GAAP Measures

This earnings release and the non-GAAP reconciliation tables included with the earnings release contain certain non-GAAP financial information, which the Company provides as additional information, and not as an alternative, to the Company's condensed consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures include (1) adjusted EBITDA, (2) adjusted EBITDA margin, (3) adjusted net income, and (4) adjusted diluted EPS. The Company provides such non-GAAP financial measures because management believes that they are useful to both management and investors as a supplement, and not as a substitute, when evaluating the Company's operating performance. Additionally, management believes that adjusted EBITDA, adjusted EBITDA margin, and adjusted diluted EPS serve as industry-wide financial measures. The Company uses adjusted EBITDA for making financial decisions, allocating resources and for determining certain incentive compensation objectives. The non-GAAP measures in this release are not in accordance with, or an alternative to, GAAP measures and may be different from non-GAAP measures, or may be calculated differently than other similarly titled non-GAAP measures, reported by other companies. They should not be used in isolation to evaluate the Company's performance. A reconciliation of non-GAAP measures identified in this release, along with further detail about the use and limitations of certain of these non-GAAP measures, may be found below in the table entitled "Non-GAAP Reconciliation Tables" under the caption entitled "Reconciliation of Non-GAAP Items" and the footnotes thereto or on the Company's website at https://ir.amnhealthcare.com/financials/quarterly-results. Additionally, from time to time, additional information regarding non-GAAP financial measures, including pro forma measures, may be made available on the Company's website.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning future demand and supply for healthcare, contingent staffing and other services, client preferences, continued growth in the markets we serve, our ongoing process and technology transformations, our ability to advance our technology-enabled workforce solutions, the future results of our strategic initiatives, fourth quarter 2026 financial projections for consolidated and segment revenue, consolidated gross margin, operating margin, SG&A as a percent of revenue, adjusted EBITDA margin, labor disruption revenue, depreciation expense, depreciation in cost of revenue, share-based compensation expense, non-cash amortization expense, integration and other expenses, interest expense, adjusted tax rate, and number of diluted shares outstanding. The Company bases these forward-looking statements on its current expectations, estimates and projections about future events and the industry in which it operates using information currently available to it. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are also identified by words such as "believe," "project," "anticipate," "expect," "intend," "plan," "will, " "may," "estimates," variations of such words and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

The targets and expectations noted in this release depend upon, among other factors, (i) the ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts, through predictive analytics, artificial intelligence, online recruiting, internal travel agencies and float pools, telemedicine or otherwise and successfully hire and retain permanent staff, (ii) the duration and extent to which hospitals and other healthcare entities adjust their utilization of temporary nurses and allied healthcare professionals, physicians, healthcare leaders and other healthcare professionals and workforce technology applications as a result of the labor market or economic conditions, (iii) the magnitude and duration of the effects of any future pandemic or health crisis on demand and supply trends, our business, its financial condition and our results of operations, (iv) our ability to effectively address client demand by attracting and placing nurses and other clinicians, (v) our ability to recruit and retain sufficient quality healthcare professionals at reasonable costs, (vi) our ability to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs and requirements, including implementing changes that will make our services more tech-enabled and integrated, (vii) our ability to manage the pricing impact that the labor market or consolidation of healthcare delivery organizations may have on our business, (viii) the effects of economic downturns, inflation or slow recoveries, which could result in less demand for our services, increased client initiatives designed to contain costs, including reevaluating their approach as it pertains to contingent labor and managed services programs, other solutions and providers, pricing pressures and negatively impact payments terms and collectability of accounts receivable, (ix) our ability to develop and evolve our current technology offerings and capabilities and implement new infrastructure and technology systems to optimize our operating results and manage our business effectively, (x) our ability and the expense to comply with extensive and complex federal and state laws and regulations related to the conduct of our operations, costs and payment for services and payment for referrals as well as laws regarding employment practices, (xi) our ability to consummate and effectively incorporate acquisitions into our business, (xii) the negative effects that intermediary organizations may have on our ability to secure new and profitable contracts, (xiii) the extent to which the Great Resignation or a future pandemic or health crisis may disrupt our operations due to the unavailability of our employees or healthcare professionals due to burnout, illness, risk of illness, quarantines, travel restrictions, mandatory vaccination requirements, or other factors that limit our existing or potential workforce and pool of candidates, (xiv) security breaches and cybersecurity incidents, including ransomware, that could compromise our information and systems, which could adversely affect our business operations and reputation and could subject us to substantial liabilities (xv) the severity and duration of the impact the labor market, economic downturn or any future pandemic or health crisis has on the financial condition and cash flow of many hospitals and healthcare systems such that it impairs their ability to make payments to us, timely or otherwise, for services rendered and (xvi) any increase to our business and operating risks as we develop new services and clients, further adopt and integrate artificial intelligence into our services and operations, enter new lines of business and focus more of our business on providing a full range of client solutions.

For a discussion of additional risk factors and a more complete discussion of some of the cautionary statements noted above that could cause actual results to differ from those implied by the forward-looking statements contained in this press release, please refer to our most recent Annual Report on Form 10-K for the year ended December 31, 2025. Be advised that developments subsequent to this press release are likely to cause these statements to become outdated and the Company is under no obligation (and expressly disclaims any such obligation) to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

Contact:

Randle Reece

Vice President, Investor Relations & Strategy

866.861.3229

 
                             AMN Healthcare Services, Inc. 
            Condensed Consolidated Statements of Comprehensive Income (Loss) 
                        (in thousands, except per share amounts) 
                                      (unaudited) 
 
                               Three Months Ended                 Nine Months Ended 
                     --------------------------------------  --------------------------- 
                          September 30,          June 30,           September 30, 
                     ------------------------  ------------  --------------------------- 
                            2026     2025          2026          2026               2025 
                     -----------  -----------  ------------  ------------  ------------- 
Revenue               $  717,272   $  634,496    $  673,237   $ 2,768,870    $ 1,982,204 
Cost of revenue          488,149      450,084       467,355     1,965,029      1,403,273 
                     -----------  -----------  ------------  ------------  ------------- 
Gross profit             229,123      184,412       205,882       803,841        578,931 
                     -----------  -----------  ------------  ------------  ------------- 
Gross margin              31.9 %       29.1 %        30.6 %        29.0 %         29.2 % 
Operating expenses: 
Selling, general 
 and administrative 
 (SG&A)                  149,267      138,594       147,391       515,083        440,909 
 SG&A as a % of 
  revenue                 20.8 %       21.8 %        21.9 %        18.6 %         22.2 % 
 
Depreciation and 
 amortization 
 (exclusive of 
 depreciation 
 included in cost 
 of revenue)              29,339       37,380        31,583        94,162        113,015 
Gain on sale of 
 disposal group               --     (39,180)            --            --       (39,180) 
Goodwill impairment 
 loss                         --           --            --            --        109,515 
Long-lived assets 
 impairment loss              --           --            --            --         18,262 
                     -----------  -----------  ------------  ------------  ------------- 
Total operating 
 expenses                178,606      136,794       178,974       609,245        642,521 
Income (loss) from 
 operations               50,517       47,618        26,908       194,596       (63,590) 
   Operating margin 
    (1)                    7.0 %        7.5 %         4.0 %         7.0 %        (3.2) % 
 
Interest expense, 
 net, and other            7,329        9,627         7,009        21,050         33,311 
                     -----------  -----------  ------------  ------------  ------------- 
 
Income (loss) 
 before income 
 taxes                    43,188       37,991        19,899       173,546       (96,901) 
 
Income tax expense 
 (benefit)                 9,794        8,703       (1,261)        56,826        (8,895) 
                     -----------  -----------  ------------  ------------  ------------- 
Net income (loss)     $   33,394   $   29,288   $    21,160   $   116,720   $   (88,006) 
                     ===========  ===========  ============  ============  ============= 
Net income (loss) 
 as a % of revenue         4.7 %        4.6 %         3.1 %         4.2 %        (4.4) % 
 
Other comprehensive 
income (loss): 
Unrealized gains 
 (losses) on 
 available-for-sale 
 securities, net, 
 and other                 (362)           80         (105)         (652)            286 
                     -----------  -----------  ------------  ------------  ------------- 
Other comprehensive 
 income (loss)             (362)           80         (105)         (652)            286 
 
Comprehensive 
 income (loss)        $   33,032   $   29,368   $    21,055   $   116,068   $   (87,720) 
                     ===========  ===========  ============  ============  ============= 
 
Net income (loss) 
per common share: 
   Basic             $      0.85  $      0.76  $       0.54  $       2.99  $      (2.29) 
                     ===========  ===========  ============  ============  ============= 
   Diluted           $      0.83  $      0.76  $       0.53  $       2.93  $      (2.29) 
                     ===========  ===========  ============  ============  ============= 
Weighted average 
common shares 
outstanding: 
   Basic                  39,109       38,619        39,021        39,012         38,449 
                     ===========  ===========  ============  ============  ============= 
   Diluted                40,165       38,693        39,732        39,800         38,449 
                     ===========  ===========  ============  ============  ============= 
 
 
                      AMN Healthcare Services, Inc. 
                  Condensed Consolidated Balance Sheets 
                          (dollars in thousands) 
                               (unaudited) 
 
                     September 30,                         September 30, 
                          2026        December 31, 2025        2025 
                    ----------------  -----------------  ----------------- 
Assets 
Current assets: 
   Cash and cash 
    equivalents      $       255,978   $         33,972    $        52,636 
   Accounts 
    receivable, 
    net                      417,585            382,560            391,100 
   Accounts 
    receivable, 
    subcontractor             42,882             48,041             51,610 
   Prepaid and 
    other current 
    assets                    87,283             80,803             74,977 
                    ----------------  -----------------  ----------------- 
      Total 
       current 
       assets                803,728            545,376            570,323 
Restricted cash, 
 cash equivalents 
 and investments              41,385             45,606             44,362 
Fixed assets, net            111,525            136,361            146,979 
Other assets                 282,783            282,552            276,764 
Deferred income 
 taxes, net                   60,739             44,877             42,637 
Goodwill                     758,999            755,809            755,809 
Intangible assets, 
 net                         233,809            283,526            302,077 
                    ----------------  -----------------  ----------------- 
      Total assets   $     2,292,968    $     2,094,107    $     2,138,951 
                    ================  =================  ================= 
 
Liabilities and 
stockholders' 
equity 
Current 
liabilities: 
   Accounts 
    payable and 
    accrued 
    expenses         $       189,926   $        161,968    $       171,135 
   Accrued 
    compensation 
    and benefits             346,149            298,837            293,182 
   Other current 
    liabilities              129,705            116,809             77,845 
                    ----------------  -----------------  ----------------- 
      Total 
       current 
       liabilities           665,780            577,614            542,162 
Revolving credit 
facility                          --             25,000                 -- 
Notes payable, net           743,370            742,053            846,759 
Other long-term 
 liabilities                 108,808            107,334            105,621 
                    ----------------  -----------------  ----------------- 
      Total 
       liabilities         1,517,958          1,452,001          1,494,542 
                    ----------------  -----------------  ----------------- 
 
Commitments and 
contingencies 
 
Stockholders' 
 equity:                     775,010            642,106            644,409 
                    ----------------  -----------------  ----------------- 
 
Total liabilities 
 and stockholders' 
 equity              $     2,292,968    $     2,094,107    $     2,138,951 
                    ================  =================  ================= 
 
 
 
                                AMN Healthcare Services, Inc. 
                   Summary Condensed Consolidated Statements of Cash Flows 
                                   (dollars in thousands) 
                                         (unaudited) 
 
                            Three Months Ended                       Nine Months Ended 
              -----------------------------------------------  ------------------------------ 
                       September 30,              June 30,             September 30, 
              -------------------------------  --------------  ------------------------------ 
                   2026             2025            2026            2026            2025 
              ---------------  --------------  --------------  --------------  -------------- 
 
Net cash 
 provided by 
 (used in) 
 operating 
 activities   $      (87,528)  $       22,666  $    (189,930)  $      284,994  $      193,885 
Net cash 
 provided by 
 (used in) 
 investing 
 activities          (18,849)          58,992        (12,210)        (38,563)          12,355 
Net cash 
 used in 
 financing 
 activities           (8,729)        (71,214)         (2,365)        (38,229)       (212,651) 
              ---------------  --------------  --------------  --------------  -------------- 
Net increase 
 (decrease) 
 in cash, 
 cash 
 equivalents 
 and 
 restricted 
 cash               (115,106)          10,444       (204,505)         208,202         (6,411) 
Cash, cash 
 equivalents 
 and 
 restricted 
 cash at 
 beginning 
 of period            390,479          72,450         594,984          67,171          89,305 
              ---------------  --------------  --------------  --------------  -------------- 
Cash, cash 
 equivalents 
 and 
 restricted 
 cash at end 
 of period     $      275,373  $       82,894  $      390,479  $      275,373  $       82,894 
              ===============  ==============  ==============  ==============  ============== 
 
 
                          AMN Healthcare Services, Inc. 
                         Non-GAAP Reconciliation Tables 
                  (dollars in thousands, except per share data) 
                                   (unaudited) 
 
                             Three Months Ended              Nine Months Ended 
                    ------------------------------------  ----------------------- 
                        September 30,         June 30,         September 30, 
                    ----------------------  ------------  ----------------------- 
                       2026        2025         2026         2026        2025 
                    ----------  ----------  ------------  ----------  ----------- 
Reconciliation of 
Non-GAAP Items: 
 
Net income (loss)   $   33,394  $   29,288   $    21,160   $ 116,720   $ (88,006) 
Income tax expense 
 (benefit)               9,794       8,703       (1,261)      56,826      (8,895) 
                    ----------  ----------  ------------  ----------  ----------- 
Income (loss) 
 before income 
 taxes                  43,188      37,991        19,899     173,546     (96,901) 
Interest expense, 
 net, and other          7,329       9,627         7,009      21,050       33,311 
                    ----------  ----------  ------------  ----------  ----------- 
Income (loss) from 
 operations             50,517      47,618        26,908     194,596     (63,590) 
Depreciation and 
 amortization           29,339      37,380        31,583      94,162      113,015 
Depreciation 
 (included in cost 
 of revenue) (2)         2,481       2,248         2,515       7,416        6,355 
Gain on sale of 
 disposal group             --    (39,180)            --          --     (39,180) 
Goodwill 
 impairment loss            --          --            --          --      109,515 
Long-lived assets 
 impairment loss            --          --            --          --       18,262 
Share-based 
 compensation            8,529       6,713         9,855      28,276       24,921 
Acquisition, 
 integration, and 
 other costs (3)         2,707       2,727         2,496       8,605       10,697 
                    ----------  ----------  ------------  ----------  ----------- 
Adjusted EBITDA 
 (4)                $   93,573  $   57,506   $    73,357   $ 333,055    $ 179,995 
                    ==========  ==========  ============  ==========  =========== 
 
Adjusted EBITDA 
 margin (5)             13.0 %       9.1 %        10.9 %      12.0 %        9.1 % 
 
Net income (loss)   $   33,394  $   29,288   $    21,160   $ 116,720   $ (88,006) 
 Adjustments: 
 Amortization of 
  intangible 
  assets                16,285      20,441        17,500      51,730       59,476 
 Acquisition, 
  integration, and 
  other costs (3)        2,707       2,727         2,496       8,605       10,697 
 Gain on sale of 
  disposal group            --    (39,180)            --          --     (39,180) 
 Goodwill 
  impairment loss           --          --            --          --      109,515 
 Long-lived assets 
  impairment loss           --          --            --          --       18,262 
 Tax effect on 
  above 
  adjustments          (4,938)       4,163       (5,199)    (15,687)     (27,537) 
 Tax effect of 
  COLI fair value 
  changes (6)            (852)     (2,848)       (5,354)     (4,141)      (4,924) 
 State tax audit 
  reserve (7)               --          --            --          --        2,889 
 Tax deficiencies 
  related to 
  equity awards 
  and ESPP (8)             107         463            65       2,323        2,750 
                    ----------  ----------  ------------  ----------  ----------- 
Adjusted net 
 income (9)         $   46,703  $   15,054   $    30,668   $ 159,550   $   43,942 
                    ==========  ==========  ============  ==========  =========== 
 
GAAP diluted net 
 income (loss) per 
 share (EPS)        $     0.83  $     0.76  $       0.53  $     2.93  $    (2.29) 
 Adjustments              0.33      (0.37)          0.24        1.08         3.43 
                    ----------  ----------  ------------  ----------  ----------- 
Adjusted diluted 
 EPS (10) (11)      $     1.16  $     0.39  $       0.77  $     4.01   $     1.14 
                    ==========  ==========  ============  ==========  =========== 
 
 
                                     AMN Healthcare Services, Inc. 
                           Supplemental Segment Financial and Operating Data 
                             (dollars in thousands, except operating data) 
                                              (unaudited) 
 
                       Three Months Ended                            Nine Months Ended 
              -------------------------------------  -------------------------------------------------- 
                  September 30,         June 30,                       September 30, 
              ----------------------  -------------  -------------------------------------------------- 
                 2026        2025         2026                 2026                      2025 
              ----------  ----------  -------------  ------------------------  ------------------------ 
Revenue 
 Nurse and 
  allied 
  solutions    $ 460,005   $ 361,476   $    421,968  $              2,009,315  $              1,156,608 
 Physician 
  and 
  leadership 
  solutions      171,208     178,214        164,582                   499,714                   526,810 
 Technology 
  and 
  workforce 
  solutions       86,059      94,806         86,687                   259,841                   298,786 
              ----------  ----------  -------------  ------------------------  ------------------------ 
               $ 717,272   $ 634,496   $    673,237  $              2,768,870  $              1,982,204 
              ==========  ==========  =============  ========================  ======================== 
 
Segment 
operating 
income (12) 
 Nurse and 
  allied 
  solutions   $   80,334  $   28,761  $      58,239                 $ 291,903                $   89,482 
 Physician 
  and 
  leadership 
  solutions       12,556      15,730         11,046                    34,420                    43,678 
 Technology 
  and 
  workforce 
  solutions       23,807      30,889         24,621                    73,698                   101,348 
              ----------  ----------  -------------  ------------------------  ------------------------ 
                 116,697      75,380         93,906                   400,021                   234,508 
Unallocated 
 corporate 
 overhead 
 (13)             23,124      17,874         20,549                    66,966                    54,513 
              ----------  ----------  -------------  ------------------------  ------------------------ 
Adjusted 
 EBITDA (4)   $   93,573  $   57,506  $      73,357                 $ 333,055                 $ 179,995 
              ==========  ==========  =============  ========================  ======================== 
 
Gross Margin 
 Nurse and 
  allied 
  solutions       30.9 %      24.1 %         28.4 %                    27.1 %                    23.5 % 
 Physician 
  and 
  leadership 
  solutions       27.0 %      27.2 %         26.5 %                    26.6 %                    27.6 % 
 Technology 
  and 
  workforce 
  solutions       47.7 %      51.5 %         48.6 %                    48.8 %                    54.1 % 
 
 
Operating 
Data: 
------------ 
Nurse and 
allied 
solutions 
 Average 
  travelers 
  on 
  assignment 
  (14)             9,486       8,203          9,194                     9,302                     8,658 
 
Physician 
and 
leadership 
solutions 
 Days filled 
  (15)            48,298      52,723         46,974                   141,917                   155,390 
 Revenue per 
  day filled 
  (16)        $    2,867  $    2,764  $       2,784                $    2,822                $    2,761 
 
 
 
                       As of September 30,   As of December 31, 
                      ---------------------  ------------------ 
                         2026       2025            2025 
                      ----------  ---------  ------------------ 
Leverage ratio (17)          1.3        3.3                 3.3 
 
 
 
                 AMN Healthcare Services, Inc. 
          Additional Supplemental Non-GAAP Disclosure 
    Reconciliation of Guidance Operating Margin to Guidance 
                    Adjusted EBITDA Margin 
                          (unaudited) 
 
                                            Three Months Ended 
                                           -------------------- 
                                            December 31, 2026 
                                           -------------------- 
                                            Low(18)   High(18) 
                                           ---------  --------- 
 
Operating margin                            (0.1 %)     0.5 % 
 Depreciation and amortization (total)       4.7 %      4.6 % 
                                           ---------  --------- 
EBITDA margin                                4.6 %      5.1 % 
 Share-based compensation                    0.9 %      0.9 % 
 Integration and other costs                 0.3 %      0.3 % 
                                           ---------  --------- 
Adjusted EBITDA margin                       5.8 %      6.3 % 
                                           =========  ========= 
 
 
 
(1)   Operating margin represents income (loss) from operations divided by 
      revenue. 
(2)   A portion of depreciation expense for AMN Language Services is included 
      in cost of revenue. We exclude the impact of depreciation included in 
      cost of revenue from the calculation of adjusted EBITDA. 
(3)   Acquisition, integration, and other costs include acquisition and 
      integration costs, net changes in the fair value of contingent 
      consideration liabilities for recently acquired companies, certain legal 
      expenses, restructuring expenses and other costs associated with exit or 
      disposal activities, and certain nonrecurring expenses, which we exclude 
      from the calculation of adjusted EBITDA, adjusted net income, and 
      adjusted diluted EPS because we believe that these expenses are not 
      indicative of the Company's operating performance. For the three and 
      nine months ended September 30, 2026, acquisition and integration costs 
      were approximately $0.8 million and $2.2 million, respectively, certain 
      legal expenses were approximately $0.4 million and $1.4 million, 
      respectively, expenses related to the closures of certain office leases 
      were approximately $0.1 million and $0.2 million, respectively, and 
      other nonrecurring expenses were approximately $1.3 million and $2.2 
      million, respectively. For the nine months ended September 30, 2026, 
      restructuring expenses and other costs associated with exit or disposal 
      activities were approximately $2.6 million. For the three and nine 
      months ended September 30, 2025, acquisition and integration costs were 
      approximately $0.8 million and $1.8 million, respectively, expenses 
      related to the closures of certain office leases were approximately $0.1 
      million and $0.5 million, respectively, certain legal expenses were 
      approximately $0.1 million and $4.4 million, respectively, restructuring 
      expenses and other costs associated with exit or disposal activities 
      were approximately $1.6 million and $2.3 million, respectively, and 
      other nonrecurring expenses were approximately $0.1 million and $1.7 
      million, respectively. 
(4)   Adjusted EBITDA represents net income (loss) plus interest expense (net 
      of interest income) and other, income tax expense (benefit), 
      depreciation and amortization, depreciation (included in cost of 
      revenue), gain on sale of disposal group, goodwill impairment loss, 
      long-lived assets impairment loss, share-based compensation, 
      acquisition, integration, and other costs, restructuring expenses, and 
      certain legal expenses. Management believes that adjusted EBITDA 
      provides an effective measure of the Company's results, as it excludes 
      certain items that management believes are not indicative of the 
      Company's operating performance. Adjusted EBITDA is not intended to 
      represent cash flows for the period, nor has it been presented as an 
      alternative to income (loss) from operations or net income (loss) as an 
      indicator of operating performance. Although management believes that 
      some of the items excluded from adjusted EBITDA are not indicative of 
      the Company's operating performance, these items do impact the statement 
      of comprehensive income (loss), and management therefore utilizes 
      adjusted EBITDA as an operating performance measure in conjunction with 
      GAAP measures such as net income (loss). 
(5)   Adjusted EBITDA margin represents adjusted EBITDA divided by revenue. 
(6)   The Company records net tax expense (benefit) related to the income tax 
      treatment of the fair value changes in the cash surrender value of its 
      company owned life insurance ("COLI"). Since this change in fair value 
      is unrelated to the Company's operating performance, we excluded the 
      impact on adjusted net income and adjusted diluted EPS. 
(7)   The Company recorded a reserve related to a state tax audit during the 
      nine months ended September 30, 2025. Since this reserve is largely 
      unrelated to our loss before taxes and is unrepresentative of our normal 
      effective tax rate, we excluded its impact in the calculation of 
      adjusted net income and adjusted diluted EPS. 
(8)   The consolidated effective tax rate is affected by the recording of tax 
      benefits and tax deficiencies related to equity awards vested during the 
      period and tax benefits recognized for disqualifying dispositions 
      related to our employee stock purchase plan ("ESPP"). The magnitude of 
      the impact of tax benefits and tax deficiencies generated in the future 
      related to equity awards and ESPP is dependent upon the Company's future 
      grants of share-based compensation, the Company's future stock price on 
      the date equity awards vest in relation to the fair value of the awards 
      on the grant date, the Company's future stock price on either the ESPP's 
      offering date or purchase date, whichever is lower, and the length of 
      time the shares issued under the ESPP are held by employees. Since these 
      tax benefits and tax deficiencies related to equity awards and ESPP are 
      largely unrelated to our income (loss) before income taxes and are 
      unrepresentative of our normal effective tax rate, we excluded their 
      impact in the calculation of adjusted net income and adjusted diluted 
      EPS. 
(9)   Adjusted net income represents GAAP net income (loss) excluding the 
      impact of the (A) amortization of intangible assets, (B) acquisition, 
      integration, and other costs, $(CUL3)$ gain on sale of disposal group, (D) 
      goodwill impairment loss, (E) long-lived assets impairment loss, (F) tax 
      effect, if any, of the foregoing adjustments, (G) net tax expense 
      (benefit) related to the income tax treatment of fair value changes in 
      the cash surrender value of its COLI, (H) tax deficiencies related to 
      equity awards vested and ESPP, and (I) state tax audit reserve. 
      Management included this non-GAAP measure to provide investors and 
      prospective investors with an alternative method for assessing the 
      Company's operating results in a manner that is focused on its operating 
      performance and to provide a more consistent basis for comparison 
      between periods. However, investors and prospective investors should 
      note that this non-GAAP measure involves judgment by management (in 
      particular, judgment as to what is classified as a special item to be 
      excluded in the calculation of adjusted net income). Although management 
      believes the items in the calculation of adjusted net income are not 
      indicative of the Company's operating performance, these items do impact 
      the statement of comprehensive income (loss), and management therefore 
      utilizes adjusted net income as an operating performance measure in 
      conjunction with GAAP measures such as GAAP net income (loss). 
(10)  Adjusted diluted EPS represents adjusted net income divided by diluted 
      weighted average common shares outstanding. Management included this 
      non-GAAP measure to provide investors and prospective investors with an 
      alternative method for assessing the Company's operating results in a 
      manner that is focused on its operating performance and to provide a 
      more consistent basis for comparison between periods. However, investors 
      and prospective investors should note that this non-GAAP measure 
      involves judgment by management (in particular, judgment as to what is 
      classified as a special item to be excluded in the calculation of 
      adjusted net income). Although management believes the items in the 
      calculation of adjusted net income are not indicative of the Company's 
      operating performance, these items do impact the statement of 
      comprehensive income (loss), and management therefore utilizes adjusted 
      diluted EPS as an operating performance measure in conjunction with GAAP 
      measures such as GAAP diluted EPS. 
(11)  As GAAP net loss is reported for the nine months ended September 30, 
      2025, basic weighted average common shares outstanding was used to 
      calculate GAAP diluted EPS for this period because the dilutive 
      potential common shares have an anti-dilutive effect (i.e., result in a 
      lower loss per share). As adjusted net income is reported for the nine 
      months ended September 30, 2025, diluted weighted average common shares 
      outstanding (including dilutive potential common shares) of 38,542, was 
      used to calculate adjusted diluted EPS. 
(12)  Segment operating income represents net income (loss) plus interest 
      expense (net of interest income) and other, income tax expense 
      (benefit), depreciation and amortization, depreciation (included in cost 
      of revenue), unallocated corporate overhead, acquisition, integration, 
      and other costs, legal settlement changes, share-based compensation, 
      goodwill impairment, long-lived assets impairment loss and gain on sale 
      of disposal group. 
(13)  Unallocated corporate overhead (as presented in the tables above) 
      consists of unallocated corporate overhead (as reflected in our 
      quarterly and annual financial statements filed with the SEC) less 
      acquisition, integration, and other costs. 
(14)  Average travelers on assignment represents the average number of nurse 
      and allied healthcare professionals on assignment during the period 
      presented. 
(15)  Days filled is calculated by dividing the locum tenens hours filled 
      during the period by eight hours. 
(16)  Revenue per day filled represents revenue of the Company's locum tenens 
      business divided by days filled for the period presented. 
(17)  Leverage ratio represents the ratio of the consolidated funded 
      indebtedness (as calculated per the Company's credit agreement) at the 
      end of the subject period to the consolidated adjusted EBITDA (as 
      calculated per the Company's credit agreement) for the twelve-month 
      period ended at the end of the subject period. 
(18)  Guidance percentage metrics are approximate. 
 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amn-healthcare-announces-third-quarter-2026-results-302931064.html

SOURCE AMN Healthcare Services, Inc.

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment